Retatrutide is an investigational medicine still in clinical trials. It is not licensed in the UK or India and is not available at our clinics. This page is provided for information only.
Retatrutide
What researchers are investigating — and what remains unknown.
What is being developed?
Retatrutide is an experimental medicine that activates three hormone receptors: GIP, GLP-1 and glucagon. A receptor is a signalling site on a cell. Researchers are studying how this combination affects weight, blood glucose and other metabolic outcomes.
Its biological activity does not establish that it is safe or appropriate outside clinical research. It has no approved treatment role at either clinic.
Where the research stands
Published phase 2 research in adults with obesity reported changes in average body weight and gastrointestinal side effects. Later trials are designed to examine benefits and harms in larger groups and different clinical settings. Results from selected trial participants are not a prediction for an individual.
Comparing percentages from different medicine trials cannot provide a reliable direct ranking. Study populations, duration and how results are analysed can differ.
Why is further research necessary?
Researchers and regulators need evidence about safety, tolerability, longer-term outcomes and manufacturing quality. A promising trial result is not a marketing authorisation. Any future approval and its conditions must be established by the relevant regulator; there is no availability date promised here.
Online products are not an approved alternative
Products sold online as retatrutide or labelled “research peptides” should not be assumed authentic, sterile or safe. Their identity, strength and purity may be unreliable. Do not use them as a substitute for regulated medical care.
If you have already used an unregulated product and feel unwell, seek medical advice. Severe or persistent abdominal pain, vomiting with dehydration or a serious allergic reaction requires urgent assessment.